Project Grant R43JG000001
Award Date 9/30/26
Completion Date 9/29/27
Dollars Obligated $45K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
United States
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Redbud Labs, Inc. $956,224 on July 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to transfer REDBUD NA1, an ultra-compact nucleic acid extraction platform, into manufacturing. REDBUD NA1 is designed for disease surveillance applications requiring qPCR and sequencing of samples from people, livestock, and wildlife. The platform addresses extraction barriers in medium-throughput translational...
- The Centers for Disease Control and Prevention awarded $613,744 to SKM Instruments, Inc. on September 30, 2025, under the Prevention of Disease, Disability, and Death by Infectious Diseases program (CFDA 93.084) to develop an ultra-rapid optical platform for antimicrobial susceptibility testing of pulmonary non-tuberculous mycobacterial infections. Performance occurs in Wyoming, with a period of performance extending through May 31, 2026. The project grant supports the development of...
- The Department of Health and Human Services Centers for Disease Control and Prevention awarded Microsensor Labs, LLC $306,872 on September 1, 2026, to develop a high-throughput automated platform for rapid isolation and testing of Salmonella. The award, made under CFDA 93.318 (Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security), runs through August 31, 2027, with place of performance in Illinois. The project is classified...
- Federal Project Grant Award Summary Pace Diagnostics, Inc. received a $600,000 Project Grant from the Centers for Disease Control and Prevention (CDC) under the CDC Investigations and Technical Assistance program (CFDA 93.283), awarded on September 30, 2025, with a completion date of March 31, 2026. The award supports the development of an ultrasensitive urine-based tuberculosis (TB) antigen rapid detection test for diagnosing active tuberculosis. This diagnostic tool represents the program's...
- <p>The Centers for Disease Control and Prevention awarded Anvil Diagnostics Inc. $296,185 on September 30, 2026, under the Protecting and Improving Health Globally program (CFDA 93.318) to develop rapid and highly multiplexed pathogen detection for sepsis patients using compressed sensing and digital PCR.</p> <p>Work is performed in Massachusetts. The period of performance runs from the award date through September 29, 2027. The assistance type is a Project Grant.</p>
- The Centers for Disease Control and Prevention awarded Advanced Virology Inc. $279,270 on September 30, 2025, under the Centers for Disease Control and Prevention Investigations and Technical Assistance program (CFDA 93.283) to develop low-cost and high-efficiency DNA-based reverse genetics platforms for manufacturing RNA virus products. The award funds work through September 29, 2027, at the recipient's Philadelphia, Pennsylvania location. The program supports investigations and technical...
- The Centers for Disease Control and Prevention awarded Esper Biosciences Inc. $614,000 on September 30, 2025, under the CDC Investigations and Technical Assistance program (CFDA 93.283) to develop a rapid point-of-care nucleic acid test for hepatitis C using nanosensors. The award period runs through September 29, 2026, with performance at Esper Biosciences' location in Ithaca, New York. The CDC Investigations and Technical Assistance program supports efforts to control communicable diseases,...
- The National Heart, Lung, and Blood Institute awarded Biochip Labs Inc. $321,229 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to manufacture and analytically validate the Microfluidic Impedance Red Cell Assay (MIRCA) for commercial viability. This Small Business Technology Transfer Phase I/II Fast-Track award funds scaling up manufacturing of the microfluidic biochip component with appropriate specifications and tight tolerances under regulated...
- The Centers for Disease Control and Prevention awarded Nanohmics Inc. $1,825,723 on September 30, 2025, under the CDC Investigations and Technical Assistance program (CFDA 93.283) to develop lateral flow-electrochemiluminescent test strips and a portable reader for ultrasensitive detection of foodborne pathogens. Performance occurs in Austin, Texas, with a completion date of September 29, 2027. The project grant supports research and development of diagnostic detection technology intended to...
- The National Institute of Allergy and Infectious Diseases awarded Pulmonescence Diagnostics Inc. $312,276 on July 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a urine-based rapid diagnostic test for pediatric tuberculosis. Pulmonescence is developing an optimized reagent formulation for a urine-based pediatric TB test adapted from its existing sputum-based diagnostic (RefTB). The work includes examining non-TB urine samples for interference with...